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Abstract
Background: The main hypothesis of this study is that Oxpentifylline administration will
effectively treat erythropoietin- or darbepoietin-resistant anaemia in chronic kidney disease
patients.
Methods/design: Inclusion criteria are adult patients with stage 4 or 5 chronic kidney disease
(including dialysis patients) with significant anaemia (haemoglobin ≤ 110 g/L) for at least 3 months
for which there is no clear identifiable cause and that is unresponsive to large doses of either
erythropoietin (≥ 200 IU/kg/week) or darbepoetin (≥ 1 μg/kg/week). Patients will be randomized
1:1 to receive either placebo (1 tablet daily) or oxpentifylline (400 mg daily) per os for a period of
4 months. During this 4 month study period, haemoglobin measurements will be performed
monthly. The primary outcome measure will be the difference in haemoglobin level between the 2
groups at the end of the 4 month study period, adjusted for baseline values. Secondary outcome
measures will include erythropoiesis stimulating agent dosage, Key's index (erythropoiesis
stimulating agent dosage divided by haemoglobin concentration), and blood transfusion
requirement.
Discussion: This investigator-initiated multicentre study has been designed to provide evidence
to help nephrologists and their chronic kidney disease patients determine whether oxpentifylline
represents a safe and effective strategy for treating erythropoiesis stimulating agent resistance in
chronic kidney disease.
Trial Registration: Australian New Zealand Clinical Trials Registry Number
ACTRN12608000199314.
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The development of erythropoiesis stimulatory agents
(ESA), such as recombinant human erythropoietin (EPO)
and darbepoetin alpha (DPO), has resulted in substantial
health benefits for patients with end-stage kidney disease
(ESKD), including improved quality of life, reduced
blood transfusion requirements, decreased left ventricular
mass, diminished sleep disturbance and enhanced exer-
cise capacity [1,2]. Unfortunately, a considerable propor-
tion of such patients exhibit a suboptimal haematologic
response to ESA, which in most cases is due to inadequate
iron supply to the erythron [3]. Other known causes of
ESA-resistance include infection, neoplasia, severe hyper-
parathyroidism, aluminium intoxication, vitamin B12
deficiency, folate deficiency, inadequate dialysis, myelo-
suppressive agents, haemoglobinopathies, myelodyspla-
sia and antibody-mediated pure red cell aplasia [4].
However, even after exclusion of these conditions, a sig-
nificant minority (approximately 10%) of patients exhibit
ESA-resistant anaemia and have been shown to have
greatly increased morbidity and mortality [4]. Inhibition
of erythropoiesis by cytokines, such as tumour necrosis
factor-α (TNF-α) and interferon-γ (IFN-γ) may play an
important role in these patients [5].
Although there is no currently effective treatment for
patients with ESA-resistant anaemia, oxpentifylline (pen-
toxifylline) may represent a promising novel therapeutic
strategy. Oxpentifylline has been used for more than
twenty years in the treatment of peripheral and cerebral
vascular diseases because of its potent haemorrheological
properties, which include preservation of erythrocyte
water and cation content [6,7]. The drug has subsequently
been found to exhibit important anti-inflammatory prop-
erties, including anti-apoptotic, anti-oxidant, anti-TNF-α
and anti-IFN-γ actions [8-11]. These actions appear to be
mediated via inhibition of phosphodiesterase [12]. Two
small, prospective, non-randomized studies have demon-
strated that oxpentifylline may significantly improve hae-
moglobin levels in chronic kidney disease patients with
ESA-resistant anaemia (vide infra) [13,14] Navarro et al
[14] treated 7 anaemic patients with advanced chronic
kidney disease (CKD) (creatinine clearance < 30 mL/min)
with oxpentifylline (400 mg daily per os) for 6 months.
Haemoglobin levels significantly increased from 99 ± 5 to
106 ± 6 g/L (p < 0.01), whilst serum TNF-α concentrations
decreased from 623 ± 366 to 562 ± 358 pg/ml (p < 0.01).
No changes were observed in untreated controls. Simi-
larly, Cooper and associates [13] administered oxpentifyl-
line (400 mg daily per os) for 4 months to 16 ESKD
patients with EPO-resistant anaemia (defined as a haemo-
globin level < 107 g/L for 6 months before treatment and
an EPO dose ≥ 12,000 IU/week). Among the 12 patients
who completed the study, mean haemoglobin concentra-
tion increased from 95 ± 9 to 117 ± 10 g/L (p = 0.0001),
whilst ex vivo T cell generation of TNF-α and IFN-γ were
significantly reduced.
Hepcidin may also play a role in ESA-resistant anaemia.
This agent is produced by hepatocytes and secreted into
the blood in response to iron status, anaemia, hypoxia
and pro-inflammatory cytokines, especially IL-6 [15-17]
and IL-1 [18]. Recently published data suggests that hep-
cidin binds to ferroportin (FPN1), a cellular iron exporter,
resulting in internalisation and loss of function [19].
FPN1 is highly expressed in macrophages of the reticu-
loendothelial system and enterocytes in the duodenum
and mediates iron release. In macrophages, the binding of
hepcidin to FPN1 and its subsequent internalisation
would result in iron accumulation within the cell and less
release of iron. Patients with CKD may have elevated lev-
els of IL-1, IL-6 and TNF-α [20,21]. It is possible that ele-
vated levels of these cytokines in CKD increase hepcidin
production and reduce iron release from macrophages in
the bone marrow resulting in reduced availability of iron
for erythropoiesis. In fact, prohepcidin was found to accu-
mulate in renal insufficiency [22,23].
In most signaling pathways involving TNF-α and IL-6, IL-
6 is a downstream component from TNF via nuclear factor
kappa B [24]. Thus, interference with TNF-α production
can interfere with IL-6 signalling. In experimental models,
oxpentifylline has been shown to reduce IL-6 expression
[25-27].
The available studies suggest that oxpentifylline may rep-
resent a significant advance in the treatment of ESA-resist-
ant anaemia in chronic kidney disease, but they are
limited by their lack of adequate controls and the associ-
ated potential for selection, observer and co-intervention
biases. A prospective, randomized, double-blind, pla-
cebo-controlled trial is required to definitively test the
hypothesis that oxpentifylline corrects ESA-resistant anae-
mia in chronic kidney patients. This study also offers the
opportunity to explore the role of the novel peptide, hep-
cidin, as a possible mediator of iron availability and ESA-
resistance.
Methods/design
Ethics approval for the Hemoglobin elevation in Erythro-
poietin Resistance with Oxpentifylline (HERO) trial has
been obtained from the local Institutional Ethics Com-
mittee in all participating centres prior to study initiation
and patient enrolment. The study will be performed in
accordance with the 2000 Edinburgh, Scotland Revision
of the Declaration of Helsinki, the National Health and
Medical Research Committee (NHMRC) Statement on
Human Experimentation, Joint NHMRC/AVCC State-
ment and Guidelines on Research Practice, applicable
ICH guidelines and the Therapeutic Goods Administra-Page 2 of 7
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(CPMP/ICH/135/95) annotated with TGA. Application
under the Clinical Trials Notification (CTN) scheme will
be required for this protocol.
Participants
The study population includes adults (18 years or over)
with stage 4 or 5 CKD (on dialysis or estimated GFR < 30
ml/min/1.73 m2) who are able to give informed consent
and who have a haemoglobin concentration < 110 g/L for
at least 3 months in spite of EPO dosage ≥ 200 IU/kg/week
or DPO dosage ≥ 1 μg/kg/week for at least 1 month.
Patients will be recruited by local investigators from par-
ticipating renal units (outpatients and dialysis units)
throughout Australia and New Zealand. The multicentre
nature of the study will greatly enhance the generalisabil-
ity of the trial.
Exclusion criteria include:
1. Patients with a history of psychological illness or con-
dition which interferes with their ability to understand or
comply with the requirements of the study.
2. Pregnancy or breast-feeding.
3. Known hypersensitivity to, or intolerance of, oxpenti-
fylline or other methylxanthines, such as caffeine, theo-
phylline or theobromine.
4. Active peptic ulcer disease.
5. Absolute or functional iron deficiency (ferritin < 100
μg/L and/or transferrin saturation < 20%).
6. Vitamin B12 or folate deficiency.
7. Parathyroid hormone level > 100 pmol/L.
8. Serum aluminium > 2 μmol/L.
9. Urea reduction ratio < 65% or single pool Kt/V < 1.0
(haemodialysis patients) or total weekly Kt/V < 1.7 (peri-
toneal dialysis patients).
10. Presence of systemic haematological disease (includ-
ing antibody-mediated pure red cell aplasia) or known
haemoglobinopathy
11. Major surgery, infection, acute myocardial infarction
or malignancy within the last 3 months.
12. Melatonin treatment, androgen therapy or blood
transfusion within the previous month.
13. Vitamin C therapy at dose greater than 100 mg/day or
at a dose which has changed within the last 3 months.
14 Haemorrhagic stroke or severe haemorrhage within the
last 3 months.
Study design
The study is an investigator-initiated, prospective, double-
blind, randomized, placebo-controlled phase 3 trial.
Patients will be randomised to one of two treatment
groups in equal proportion (Fig. 1). To ensure adequate
concealment of allocation, the randomization will be per-
formed using a central computer and web-based link to
the central database provided through the Australasian
Kidney Trials Network (AKTN). Patients will be rand-
omized in permuted blocks with stratification for centre
and disease stage/dialysis type.
Experimental intervention
The experimental intervention will be oxpentifylline (400
mg daily per os; Trental®, Sanofi-Aventis, Sydney, Aus-
tralia). Oxpentifylline is registered in Australia for treat-
ment of intermittent claudication on the basis of chronic
arterial occlusive disease of the limbs. The standard dose
is 400 mg three times daily. The dose of oxpentifylline
selected for this study (400 mg daily) is lower than the
standard dose because the drug may accumulate in renal
failure. Moreover, this dose has been shown to be effica-
cious without significant side effects in 23 ESKD patients
studied by Cooper et al [13] and Navarro et al [14]
Schema for the HERO TrialFigure 1
Schema for the HERO Trial.Page 3 of 7
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The control intervention will be placebo (1 tablet daily
per os).
Concurrent treatments
Iron supplementation will be performed according to
usual protocol (note that randomisation will be stratified
for centre). Vitamin B and folic acid supplementation are
permitted. Melatonin and androgen therapy are pro-
scribed during the study period. If the patient is taking
vitamin C, the daily dose will be kept constant throughout
the study period. Erythropoietin (EPO) or darbepoetin
(DPO) dosages will not be increased during the study, and
will only be reduced if haemoglobin levels rise above 125
g/L.
Blinding
Patients, investigators and outcome assessors will be
blinded to the treatment allocation.
Outcome measures
The primary outcome measure will be the difference in
haemoglobin concentration between the oxpentifylline
and control groups at the end of the 4 month study
period.
Secondary outcome measures include:
a. Difference in the dosage of erythropoiesis stimulating
agents (ESA; either erythropoietin or darbepoetin)
between the oxpentifylline and control groups at the end
of the 4 month study period.
b. Difference in Key's index (ESA dosage divided by hae-
moglobin concentration) between the oxpentifylline and
control groups at the end of the 4 month study period.
c. Difference in frequency of blood transfusion require-
ments between the oxpentifylline and control groups dur-
ing the 4 month study period.
d. Occurrence of adverse events in the oxpentifylline and
control groups during the 4 month study period.
Exploratory outcome measures that will be studied
include the differences in serum concentrations of hepci-
din and biomarkers of inflammation (TNF-α, interferon-
γ, IL-6 and IL-1) and oxidative stress (isoprostanes, pro-
tein carbonyls, plasma catalase and glutathione peroxi-
dase activity) between the oxpentifylline and control
groups at the end of the 4 month trial.
Clinical assessment of outcome
Full blood counts will be measured monthly, as per usual
clinical practice. Iron studies will be measured every 2
months. Patients will receive a medical review every 2
months. An individual patient's participation in the study
will cease at the end of the 4 month study period. If,
before this time, the patient experiences severe anaemia (<
65 g/L), symptomatic anaemia or the patient's attending
physician believes that additional therapy is required (eg
blood transfusion), they will be considered to have
reached an end-point and will be withdrawn from study
medication, but will still have blood counts measured
monthly and followed for study outcomes.
The number and proportion of subjects who report treat-
ment-emergent adverse events will be summarized for
each treatment group. Treatment emergent events include
events that start on or after Day 0 of the study [that is the
first day of Study Drug administration], and were not
present at baseline, or were present at baseline, but
increased in severity after the start of the study. The Medi-
cal Dictionary for Regulatory Activities [MedDRA] Termi-
nology will be used to classify all adverse events with
rESAect to System Organ Class [SOC], high level group
term (HLGT), and preferred term.
Sample size calculations
Prospective power calculations based on unpaired t-test
comparisons indicate that the study will have adequate
statistical power (90% probability) to detect a clinically
significant increase in haemoglobin concentration of 10
g/L, assuming alpha = 0.05 and a population standard
deviation of 12 g/L, if 62 patients were recruited in the
study (31 in each group). Allowing for a 5% drop-out rate
and a 20% non-compliance rate, we aim to recruit a total
of 110 patients (55 in each group) across all centres. We
anticipate that this will require a recruitment period of 6
months.
Statistical analyses
Differences between the intervention and control groups
with respect to the primary outcome measure (haemo-
globin level at 4 months) will be measured by comparison
of the mean haemoglobin in each group, adjusted for
baseline values (analysis of covariance). Data will be ana-
lysed on an intention to treat basis. For patients withdraw-
ing before the end of the 4 month study, their
haemoglobin at the time of withdrawal will be taken as
their final haemoglobin. A sub-analysis will be performed
to determine whether patients with significantly elevated
C-reactive protein (CRP) levels (above the local labora-
tory's reference range) are more likely to have oxpentifyl-
line-responsive anaemia. The data will be analysed by t-
test and by repeated measures analysis of covariance.
Because of power considerations and the relatively short
duration of the study, no interim analysis is planned.Page 4 of 7
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ures analysis of covariance with and without adjustment
for baseline characteristics. The analyses used for second-
ary outcome measures will include unpaired t-test (Key's
index), Mann-Whitney U-test (ESA dosage) and chi
square test (blood transfusion requirement, adverse drug
reactions).
Categorical baseline characteristics (e.g. sex, race, comor-
bid illnesses, etc) will be summarized with the number
and percent of subjects in each treatment group with the
characteristic. Quantitative characteristics (e.g. age and
weight) will be summarized by mean and standard devia-
tion or median [interquartile range], depending on data
distribution. The number and percent of subjects who are
randomized, treated with randomized Study Drug,
require intervention, prematurely discontinue, and com-
plete the study will be summarized. Fisher's exact test or
the Chi-square test will be used to assess treatment group
differences in the proportions of subjects who require
intervention and who complete the study. The number
and percent of subjects will be summarized for each rea-
son for premature discontinuation.
Discussion
This invesigator-initiated, multicentre Australian and New
Zealand study has been designed to provide evidence to
help nephrologists and their CKD patients better deter-
mine whether Oxpentifylline (Trental®) administration
will safely and effectively treat erythropoietin- or darbe-
poietin-resistant anaemia. Given that numerous studies
have demonstrated that ESA hyporesponsive patients are
at significantly increased risk of mortality [28], novel
treatments for correcting anaemia in this group (such as
with oxpentifylline) may represent an important strategy
for improving clinical outcomes. The multicentre nature
of the trial will greatly enhance its generalisability. More-
over, the trial sample size has been carefully and prospec-
tively calculated using a minimum clinically important
difference in haemoglobin level of 10 g/L and realistic
estimates of trial drop-out and non-compliance rates to
minimise the risk of a type 2 statistical error. Demonstra-
tion of a significant improvement in haemoglobin levels
with oxpentifylline therapy will provide clinicians with an
important new strategy for effectively treating ESA-resist-
ant anaemia. On the other hand, a negative study will dis-
suade clinicians from unnecessarily exposing patients to
oxpentifylline (which has a small potential for side
effects) if it is proven to lack efficacy with respect to treat-
ing ESA-resistant anaemia.
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